RxDoctor Payments Data

Konstantins Kociasvili, MD

Adult Medicine · Glenview, ILNPI 1588854848

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Pfizer at 39.8% of the total. Reporting peaked in 2019 at $310 and has fallen 86.3% since, to $42 in 2025.

$534in general payments, 2019–2025

Across 29 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$213
  • AstraZeneca$115
  • Amgen$55
  • AbbVie$47
  • Lilly USA, LLC$20
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$534 in reported general payments places this provider in the 75th percentile of 39 adult medicine providers in Illinois.

See all adult medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$117,792
Medicare patients
319
Services billed
2,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$50,371
JardianceEmpagliflozin48$44,049
FarxigaDapagliflozin Propanediol43$33,765
JanuviaSitagliptin Phosphate26$26,973
LinzessLinaclotide44$25,688
TrulicityDulaglutide13$12,442
Sumatriptan14$2,838
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen66$1,814
Atorvastatin Calcium246$1,685
Metoprolol Succinate136$1,426
Cefpodoxime Proxetil30$1,333
Omeprazole82$1,014
Fenofibrate45$937
Gabapentin43$705
Pantoprazole Sodium77$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$213$50,37162 claims
AstraZenecaFarxiga$115$33,76543 claims
AbbVieLinzess$47$25,68844 claims
Lilly USA, LLCTrulicity$20$12,44213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 adult medicine providers in Illinois.

Other adult medicine in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →